Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Greece
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 4Not yet taking people in GreeceAsciminib Roll-over Study
- Where
- Athens, Thessaloniki
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in GreeceA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Athens, Heraklion, Patras, Thessaloniki
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 2Active, not recruitingA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Athens, Ioannina, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - Phase 3Taking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Athens, Chaïdári, Ioannina, Patras, Thessaloniki
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Athens, Rio Patras, Thessaloniki
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Athens, Ioannina, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 3Taking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Athens, Ioannina, Pátrai, Thessaloniki
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135